Traders sold shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on strength during trading hours on Thursday. $287.60 million flowed into the stock on the tick-up and $317.08 million flowed out of the stock on the tick-down, for a money net flow of $29.48 million out of the stock. Of all equities tracked, Valeant Pharmaceuticals International had the 0th highest net out-flow for the day. Valeant Pharmaceuticals International traded up $1.40 for the day and closed at $23.02

A number of research firms recently weighed in on VRX. Rodman & Renshaw restated a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, July 6th. Stifel Nicolaus restated a “buy” rating and issued a $55.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, July 6th. Wells Fargo & Co. restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, June 29th. BMO Capital Markets began coverage on Valeant Pharmaceuticals International in a research report on Tuesday, June 28th. They issued a “market perform” rating and a $26.00 target price for the company. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 27th. Seven investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average price target of $66.43.

The company’s market cap is $7.84 billion. The company has a 50 day moving average price of $23.51 and a 200-day moving average price of $49.66.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The company earned $2.37 billion during the quarter, compared to analysts’ expectations of $2.34 billion. The business’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.36 earnings per share. Equities analysts anticipate that Valeant Pharmaceuticals International Inc. will post $6.63 EPS for the current year.

In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa purchased 202,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was purchased at an average cost of $24.48 per share, with a total value of $4,944,960.00. Following the purchase, the chief executive officer now owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several large investors have modified their holdings of VRX. Vanguard Group Inc. raised its stake in shares of Valeant Pharmaceuticals International by 8.0% in the fourth quarter. Vanguard Group Inc. now owns 4,440,755 shares of the specialty pharmaceutical company’s stock worth $451,403,000 after buying an additional 330,079 shares in the last quarter. I.G. Investment Management LTD. raised its stake in shares of Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock worth $135,033,000 after buying an additional 314,616 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock worth $28,900,000 after buying an additional 203,760 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock worth $30,635,000 after buying an additional 131,832 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Valeant Pharmaceuticals International by 64.4% in the fourth quarter. New York State Common Retirement Fund now owns 276,226 shares of the specialty pharmaceutical company’s stock worth $28,078,000 after buying an additional 108,175 shares in the last quarter.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.